Parasites and blood transfusion: Causes and consequences;Parasites et transfusion sanguine: Causes et conséquences

Hematologie

Volumn 12, Issue 2, 2006, Pages 129-139

  El Ghouzzi, Marie Hélène ^a   Garraud, Olivier ^a,b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Babesiosis; Chagas disease; Leishmaniosis; Malaria; Transfusion; Transfusion transmitted protozoal infection

Indexed keywords

AFRICAN TRYPANOSOMIASIS; BABESIA; BABESIOSIS; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; CHAGAS DISEASE; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMIGRATION; INDUSTRIALIZATION; LEISHMANIA; LEISHMANIASIS; LOWEST INCOME GROUP; MALARIA; PARASITE; PARASITE TRANSMISSION; PLASMODIUM; POPULATION DYNAMICS; PROTOZOON; REVIEW; TICK BORNE DISEASE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRYPANOSOMA CRUZI; VIRUS INFECTION;

EID: 33744814615     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Pillonel J, Laperche S, Groupe «Agents Transmissibles par Transfusion» de la Société française de transfusion sanguine, Etablissement français du sang, Centre de transfusion sanguine des armées. Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing). Transfus Clin Biol 2004; 11: 81-6.
2. Hergon E, Moutel G, Duchange N, Bellier L, Rouger P, Herve C. Risk management in transfusion after the HIV blood contamination crisis in France: The impact of the precautionary principle. Transfus Med Rev 2005; 19: 273-80.
3. Brown P. Pathogenesis and transfusion risk of transmissible spongiform encephalopathies. Dev Biol 2005; 120: 27-33.
4. Bruneel F, Thellier M, Eloy O, et al. Transfusion-transmitted malaria. Intensive Care Med 2004; 30: 1851-2.
5. Kitchen AD, Barbara JA, Hewitt PE. Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines. Vox Sang 2005; 89: 77-80.
6. Garraud O. Parasites and blood transfusion: immunity to these parasites and how is the risk of transmission from donor to receiver covered? In: Garraud O, ed. Update in Tropical Immunology. Trivandrum, India: Research Signpost, Fort PO, 2005: 401-17.
7. Pantanowitz L, Telford 3rd SR, Cannon ME. The impact of babesiosis on transfusion medicine. Transfus Med Rev 2002; 16: 131-43.
8. Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res Rev 2005; 6: 41-61.
9. Denkers EY, Butcher BA, Del Rio L, Bennouna S. Neutrophils, dendritic cells and Toxoplasma. Int J Parasitol 2004; 34: 411-21.
10. Collet G, Marty P, Le Fichoux Y, et al. Pleural effusion as the first manifestation of pulmonary toxoplasmosis in a bone marrow transplant recipient. Acta Cytol 2004; 48: 114-6.
11. http://www.who.int/leishmaniasis/.
12. Basset D, Pratlong F, Ravel C, et al. Les leishmanioses déclarées en France en 1999. Bull Epidemiol Hebd 2001; 5: 19-21.
13. Luz KG, da Silva VO, Gomes EM, et al. Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and multiply transfused hemodialysis patients. Am J Trop Med Hyg 1997; 57: 168-71.
14. Mathur P, Samantaray JC. The first probable case of platelet transfusion-transmitted visceral leishmaniasis. Transfus Med 2004; 14: 319-21.
15. Grogl M, Daugirda JL, Hoover DL, Magill AJ, Berman JD. Survivability and infectivity of viscerotropic Leishmania tropica from Operation Desert Storm participants in human blood products maintained under blood bank conditions. Am J Trop Med Hyg 1993; 49: 308-15.
16. Basset D, Pratlong F, Ravel C, et al. Les leishmanioses autochtones et d'importationen France pour l'année 2000. In: Surveillance nationale des maladies infectieuses (InVS). http://www.invs.sante.fr/.
17. Bregani ER, Balzarini L, Ghiringhelli C, Tarsia P. Transfusional Mansonella perstans microfilariasis. Parasitologia 2003; 45: 71-2.
18. Garraud O, ElGhouzzi MH. Le risque parasitaire transfusionel: quels contrôles au regard de la directive européenne? Transfus Clin Biol 2005; 12: 275-85.
19. http://who.int/topics/malaria/en/.
20. Danis M, Legros F, Thellier M, Caumes E. Current data on malaria in metropolitan France. Med Trop 2002; 62: 214-8.
21. Karunaweera ND, Wijesekera SK, Wanasekera D, Mendis KN, Carter R. The paroxysm of vivax malaria. Trends Parasitol 2003; 19: 188-93.
22. Cartron JP, Bailly P, Le Van Kim C, et al. Insights into the structure and function of membrane polypeptides carrying blood group antigens. Vox Sang 1998; 74(Suppl 2): 29-64.
23. Hartl DL. The origin of malaria: mixed messages from genetic diversity. Nat Rev Microbiol 2004; 2: 15-22.
24. Candolfi E. Transfusion-transmitted malaria, preventive measures. Transfus Clin Biol 2005; 12: 107-13.
25. Garraud O, Mahanty S, Perraut R. Malaria specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol 2003; 24: 30-5.
26. Garraud O, Relave J, Flori P, Perraut R. Le risque de paludisme transfusionnel confronté à celui de la mutité biologique: deux données irréconciliables? Transfus Clin Biol 2004; 11: 87-94.
27. Korbel DS, Finney OC, Riley EM. Natural killer cells and innate immunity to protozoan pathogens. Int J Parasitol 2004; 34: 1517-28.
28. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344: 1973-8.
29. http://who.int/topics/chagas_disease/en/.
30. Carme B, Aune I, Nguyen G, et al. Four cases of acute chagasic myocarditis in French Guiana. Am J Trop Med Hyg 2001; 64: 162-3.
31. Leiby DA. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion 1999; 39: 310-5.
32. Aznar C, La Ruche G, Laventure S, Carme B, Liegeard P, Hontebeyrie M. Seroprevalence of Trypanosoma cruzi infection in French Guiana. Mem Inst Oswaldo Cruz 2004; 99: 805-8.
33. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001; 1: 92-100.
34. Dura WO, Rocha MO, Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasitol 2005; 21: 581-7.
35. Andrade LO, Andrews NW. The Trypanosoma cruzi-host cell interplay: localization, invasion, retention. Nat Rev Microbiol 2005; 3: 819-23.
36. Schmunis GA. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz 1999; 94(Suppl. 1): 93-101.
37. Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med 1999; 341: 1237-9.
38. Grant IH, Gold JWM, Wittner M, et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med 1989; 111: 849-51.
39. Gudino MD, Linares J. In: Chagas disease and blood transfusion: emerging global patterns in transfusion transmitted infections. Proceedings AABB conference, Arlington, VA. 1990: 65-86.
40. Winckler P, Telleiria J, Bosseno MF, et al. PCR-based diagnosis for Chagas' disease in Bolivian children living in an active transmission area: comparison with conventional serological and parasitological diagnosis. Parasitology 1997; 114: 367-73.
41. Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening in a hyperendemic region. Transfusion 2005; 45: 554-61.
42. Reina-San-Martin B, Degrave W, Rougeot C, et al. A B-cell mitogen from a pathogenic trypanosome is a eukaryoteic proline racemase. Nat Medecine 2000; 6: 890-7.
43. Palomiro SA, Aillo VD, Higuchi ML. Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi. Ann Trop Med Parasitol 2000; 94: 571-9.
44. Reesink HW, Engelfriet CP. Are current measures to prevent transfusion-associated protozoal infections sufficient? Vox Sang 2004; 87: 125-38.
45. Reesink HW. European strategies against the parasite transfusion risk. Transfus Clin Biol 2005; 12: 1-4.
46. Garraud O, Andreu G, ElGhouzzi MH, Laperche S, Lefrère JJ. Measures to prevent transfusion-associated protozoal infections in non-endemic countries. J Travel Infect Dis 2006; (sous presse).
47. Corash L. Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001; 8: 138-45.
48. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49.